
Dr Joahn Conradie
WA-developed blood tests bring new innovation to primary care
New blood tests developed here in WA are helping GPs manage significant health burdens.
About the Author

Dr Joahn Conradie

Western Australia has a strong history of medical and scientific innovation, with two locally developed blood tests now bringing that innovation into clinical practice.
Promarker®D and Promarker®Eso were developed by WA-based Proteomics International and are now available nationwide exclusively through the Healius Pathology Network, including Western Diagnostic Pathology in WA.
For GPs, PromarkerD provides information about the risk of future kidney function decline in adults with type 2 diabetes, while Promarker Eso supports assessment of possible oesophageal adenocarcinoma (EAC).
Both combine protein biomarkers with clinical variables in validated algorithms to provide individualised results that complement established clinical assessment.
Identifying kidney disease risk earlier
Diabetes-related kidney disease represents a significant health burden in Australia. Australian Institute of Health and Welfare (AIHW) analysis of the 2022/24 National Health Measures Survey indicates that approximately 470,000 Australian adults had diabetes and biomedical signs of chronic kidney disease.
In its 2023 report, Diabetes Australia estimated the annual cost of diabetes-related kidney disease to the healthcare system was around $2.68 billion.
PromarkerD is a blood test designed to assess the risk of future kidney function decline in adults with type 2 diabetes. Notably, its clinical validation included the Fremantle Diabetes Study Phase II in WA, where it demonstrated an ability to predict incident diabetic kidney disease and significant eGFR decline over four years.
International validation using data from the CANVAS study subsequently demonstrated its prognostic utility for incidence of CKD.
It measures the protein biomarkers apolipoprotein A-IV (ApoA4) and CD5 antigen-like (CD5L), combining biomarker and clinical information to generate an individualised risk assessment.
For GPs, this can provide additional prognostic information alongside established kidney health assessments and may help identify patients who could benefit from closer monitoring and earlier consideration of appropriate lifestyle and medical management.
This is particularly relevant given gaps in routine kidney monitoring. Diabetes Australia’s 2023 report found fewer than one in four Australians living with diabetes received kidney checks within recommended timeframes.
Oesophageal cancer risk assessment
The PromarkerEso test is designed to support assessment for EAC by measuring four serum glycoprotein biomarkers and combining these with age, sex and body mass index (BMI) to categorise a patient’s probability of EAC.
A 2025 study involving 259 samples across one development cohort and two independent validation cohorts demonstrated strong discrimination between EAC and controls.
These findings should be interpreted in the context of the study populations and do not establish equivalent performance in an unselected primary care population.
For GPs assessing appropriate patients with chronic gastro-oesophageal reflux disease (GORD) and recognised EAC risk factors, PromarkerEso provides an additional source of clinical information to help support risk stratification and decisions about further investigation or specialist referral.
PromarkerEso is designed to complement existing clinical evaluation and diagnostic pathways, rather than replace endoscopy where clinically indicated. A low probability result should not delay further investigation when symptoms or clinical findings warrant it.
WA innovation to clinical practice
The development of PromarkerD and PromarkerEso in WA demonstrates the increasing role pathology can play in preventative health, using new diagnostic technologies to support earlier risk assessment and more personalised care.
Making innovative tests available is only part of the partnership the Healius Pathology Network offers primary care. Practical, evidence-based, pathology-led online education for GPs is provided by Healius including clinical audits and free CPD education, with education affiliated and accredited with RACGP, ACRRM, AMA CPD Home and SCCA.
GPs can access dedicated accredited online education about PromarkerD and PromarkerEso through the Healius GP education portal, including information about the biomarkers and clinical variables used by the tests.
Through Western Diagnostic Pathology in WA and its broader national network, Healius is helping connect GPs with pathology expertise, education and novel diagnostic innovation that can support more informed and personalised patient care.
Resources: www.education.healius.com.au/blog/promarker-tests-available